Advertisement

Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 749–750 | Cite as

ASO Author Reflections: Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Gastric Cancer

  • In-Hwan Kim
ASO Author Reflections

Notes

DISCLOSURES

In-Hwan Kim has no conflicts of interest to disclose.

References

  1. 1.
    Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.CrossRefGoogle Scholar
  2. 2.
    Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–96.CrossRefGoogle Scholar
  3. 3.
    Kim IH, Park SS, Lee CM, et al. Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review. Ann Surg Oncol. 2018;25:1176–83.CrossRefGoogle Scholar
  4. 4.
    Hamada C, Yamada Y, Azuma M, et al. Meta-analysis supporting noninferiority of oxaliplatin plus S-1 to cisplatin plus S-1 in first-line treatment of advanced gastric cancer (G-SOX study): indirect comparison with S-1 alone. Int J Clin Oncol. 2016;21:668–75.CrossRefGoogle Scholar
  5. 5.
    Chen LT, Oh DY, Ryu MH, et al. Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: a systematic review. Cancer Res Treat. 2017;49:851–68.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Department of SurgeryDaegu Catholic University School of MedicineDaeguSouth Korea

Personalised recommendations